HC Wainwright Analysts Lift Earnings Estimates for Evommune

Evommune logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright raised its FY2026 EPS estimate for Evommune to a loss of $3.28 per share from a projected loss of $3.41, while keeping a Neutral rating.
  • Evommune reported a quarterly loss of $0.85 per share, missing the consensus estimate of a $0.82 loss; its shares were down 7.1% and opened at $7.09.
  • Analyst sentiment overall is a Moderate Buy, with an average price target of $30.50, though several firms recently lowered their targets.
  • MarketBeat previews the top five stocks to own by December 1st.

Evommune, Inc. (NYSE:EVMN - Free Report) - Research analysts at HC Wainwright raised their FY2026 earnings per share (EPS) estimates for Evommune in a research report issued on Friday, November 13th. HC Wainwright analyst M. Kapoor now anticipates that the company will earn ($3.28) per share for the year, up from their prior forecast of ($3.41). HC Wainwright has a "Neutral" rating on the stock. The consensus estimate for Evommune's current full-year earnings is ($3.35) per share. HC Wainwright also issued estimates for Evommune's Q4 2026 earnings at ($0.88) EPS, Q1 2027 earnings at ($0.84) EPS, Q2 2027 earnings at ($0.83) EPS, Q3 2027 earnings at ($0.86) EPS, Q4 2027 earnings at ($0.91) EPS and FY2027 earnings at ($3.45) EPS.

A number of other equities research analysts also recently issued reports on the stock. Royal Bank Of Canada reduced their price objective on shares of Evommune from $29.00 to $21.00 and set an "outperform" rating on the stock in a research note on Wednesday, September 9th. Weiss Ratings cut shares of Evommune from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Friday, September 11th. Leerink Partners cut their price target on shares of Evommune from $28.00 to $22.00 and set an "outperform" rating for the company in a report on Wednesday, September 9th. Raymond James Financial set a $18.00 price objective on shares of Evommune in a research report on Wednesday, September 9th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Evommune in a research report on Friday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Evommune has an average rating of "Moderate Buy" and an average price target of $30.50.

Read Our Latest Report on EVMN

Evommune Stock Down 7.1%

EVMN stock opened at $7.09 on Tuesday. Evommune has a 52 week low of $4.94 and a 52 week high of $33.20. The business has a 50-day simple moving average of $7.45 and a 200 day simple moving average of $17.04. The company has a market cap of $257.24 million and a PE ratio of -1.86.

Evommune (NYSE:EVMN - Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.03).

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Janus Henderson Group PLC acquired a new stake in shares of Evommune in the 1st quarter valued at approximately $20,615,000. Stempoint Capital LP grew its holdings in shares of Evommune by 184.1% during the 1st quarter. Stempoint Capital LP now owns 193,777 shares of the company's stock valued at $4,385,000 after purchasing an additional 125,581 shares during the last quarter. Perceptive Advisors LLC acquired a new position in Evommune during the 1st quarter worth approximately $10,308,000. Defilade Capital Management L.P. increased its position in Evommune by 215.0% during the 1st quarter. Defilade Capital Management L.P. now owns 678,589 shares of the company's stock worth $15,601,000 after purchasing an additional 463,171 shares in the last quarter. Finally, Eversept Partners LP bought a new position in Evommune in the 1st quarter valued at approximately $1,257,000.

Evommune Company Profile

(Get Free Report)

Evommune is a clinical-stage biotechnology company developing therapies for chronic inflammatory diseases. Founded in 2020, the company focuses on biological pathways involved in inflammation and aims to develop treatments for conditions with significant unmet medical needs. Its pipeline includes EVO756, an oral investigational medicine designed to block MRGPRX2, a receptor involved in mast-cell activation. The candidate is being studied for inflammatory skin disorders, including chronic spontaneous urticaria and atopic dermatitis.

Featured Articles

Earnings History and Estimates for Evommune (NYSE:EVMN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Evommune Right Now?

Before you consider Evommune, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evommune wasn't on the list.

While Evommune currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines